Repligen Corporation (RGEN)
| Market Cap | 6.90B +2.2% |
| Revenue (ttm) | 763.34M +17.4% |
| Net Income | 51.40M |
| EPS | 0.91 |
| Shares Out | 56.41M |
| PE Ratio | 134.43 |
| Forward PE | 58.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 693,726 |
| Open | 125.95 |
| Previous Close | 126.55 |
| Day's Range | 121.69 - 128.36 |
| 52-Week Range | 100.99 - 175.77 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 176.11 (+43.99%) |
| Earnings Date | Jul 28, 2026 |
About RGEN
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spect... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $176.11, which is an increase of 43.99% from the latest price.
News
Repligen Transcript: 46th Annual William Blair Growth Stock Conference
Innovation and diversification are fueling strong growth, with a focus on expanding in Asia, accelerating digital transformation, and improving operational efficiency. Despite headwinds, analytics and chromatography are driving robust performance, and the company is confident in meeting its financial guidance.
Repligen Slides: 46th Annual William Blair Growth Stock Conference
Repligen has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Repligen price target lowered to $150 from $170 at HSBC
HSBC lowered the firm’s price target on Repligen (RGEN) to $150 from $170 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
Repligen assumed with an Outperform at Wolfe Research
Wolfe Research assumed coverage of Repligen (RGEN) with an Outperform rating and $145 price target The company is a bioprocessing pure play with highly differentiated products in sub-segments like ups...
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in...
Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of ...
Repligen resumed with an Outperform at RBC Capital
RBC Capital analyst Dan Leonard resumed coverage of Repligen (RGEN) with an Outperform rating and $160 price target The firm believes the strengthening of the bioprocess market and the diversity…
Repligen Transcript: AGM 2026
The meeting was held virtually, covering director elections, auditor ratification, and executive compensation. All proposals were recommended for approval, with no questions raised by shareholders. Voting was conducted online, and the meeting concluded smoothly.
Repligen Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 results exceeded expectations, supporting raised EPS guidance and confidence in annual targets. Growth was led by proteins, chromatography, and analytics, while new modalities and ATF faced temporary headwinds. Strategic initiatives, including a Transformation Office and China OEM partnership, aim to drive sustainable margin expansion and future growth.
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in...
Repligen price target raised to $160 from $145 at Barclays
Barclays raised the firm’s price target on Repligen (RGEN) to $160 from $145 and keeps an Overweight rating on the shares.
Repligen price target lowered to $165 from $180 at JPMorgan
JPMorgan lowered the firm’s price target on Repligen (RGEN) to $165 from $180 and keeps an Overweight rating on the shares.
Repligen price target lowered to $142 from $152 at Jefferies
Jefferies analyst Matthew Stanton lowered the firm’s price target on Repligen (RGEN) to $142 from $152 and keeps a Hold rating on the shares. Q1 was “enough” against a bar…
Repligen Earnings Call Transcript: Q1 2026
Q1 2026 delivered 15% revenue growth (11% organic), strong margin expansion, and robust performance across all segments and geographies. Guidance for 2026 was raised for adjusted EPS and operating income, with strategic initiatives and a new China partnership positioning the company for continued outperformance.
Repligen Earnings release: Q1 2026
Repligen released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Repligen Slides: Q1 2026
Repligen has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Repligen Quarterly report: Q1 2026
Repligen has published its Q1 2026 quarterly earnings report on May 5, 2026.
Repligen raises FY26 EPS view to $1.97-$2.05 from $1.93-$2.10, consensus $1.97
Cuts FY26 revenue view to $803M-$833M from $810M-$840M, consensus $827.74M. The company said, “We also continue to make meaningful progress on our strategic priorities. We launched a Transformation Of...
Repligen reports Q1 adjusted EPS 48c, consensus 38c
Reports Q1 revenue $194.26M, consensus $192.17M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We delivered a very strong start to the year, achieving 11% organic r...
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi...
Repligen Proxy statement: Proxy filing
Repligen filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Repligen to Report First Quarter 2026 Financial Results
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET
Repligen price target lowered to $145 from $165 at Canaccord
Canaccord lowered the firm’s price target on Repligen (RGEN) to $145 from $165 and keeps a Hold rating on the shares. The firm updated its model ahaead of Q1 results…
Repligen opens new Training & Innovation Center in Netherlands
Repligen (RGEN) Corporation announced the grand opening of its new Repligen Training & Innovation Center at its OPUS Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands....
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its ...